Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss - finance.yahoo.com
Why now
Thesis: Sanofi M&A hunt offsets Dupixent patent-loss cliff
Catalyst to watch: New deal announcements or pipeline data
Main risk: Dealmaking fails to replace lost exclusivity
Why it matters
Sanofi's Dupixent growth ambitions and M&A search ahead of patent losses highlight pharma's reliance on dealmaking to offset exclusivity cliffs, a read-across for large-cap pharma pipelines.
Related assets & topics
AstraZeneca · AZNSources
- googlenews · news.google.com · 2026-09-20 08:01 UTC
- googlenews · news.google.com · 2026-09-20 08:01 UTC